Novartis to add radioligand therapy manufacturing facility in Florida

Novartis (NVS) announced plans to build its fourth U.S. radioligand therapy manufacturing facility in Winter Park, Florida. “The built-for-purpose, state-of-the-art facility represents another milestone in the company’s $23B U.S. investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling U.S. manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live. The new 35,000-square-foot facility in Winter Park, Florida, will come online by 2029 and will strengthen Novartis’ specialized supply chain and manufacturing capabilities across its network of RLT production facilities. The new facility will optimize the delivery of RLT medicines to patients in the southeast US and help maintain the company’s steady rate of greater than 99% of doses administered on the planned day as the potential for this promising treatment modality continues to expand,” the company stated.